HARARE – Zimbabwe has introduced a new user-friendly Anti-Retroviral Treatment (ARV) drug which experts say has fewer side effects on users, and also increases adherence to treatment. The new combination drug called Tenofovir, Lamivudine, Efavirenz — also known as TLE400 — is said to be the current treatment of choice globally in the first line…
To access this content, please purchase a subscription by clicking the button below and select a package of your choice!
Subscriptions